JP6975709B2 - 安定化したウイルスクラスｉ融合タンパク質 - Google Patents

安定化したウイルスクラスｉ融合タンパク質 Download PDF

Info

Publication number
JP6975709B2
JP6975709B2 JP2018511416A JP2018511416A JP6975709B2 JP 6975709 B2 JP6975709 B2 JP 6975709B2 JP 2018511416 A JP2018511416 A JP 2018511416A JP 2018511416 A JP2018511416 A JP 2018511416A JP 6975709 B2 JP6975709 B2 JP 6975709B2
Authority
JP
Japan
Prior art keywords
protein
fusion
amino acid
class
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018511416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529331A (ja
JP2018529331A5 (cg-RX-API-DMAC7.html
Inventor
ランゲディク，ヨハンネス，ペトリュス，マリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Janssen Vaccines and Prevention BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines and Prevention BV filed Critical Janssen Vaccines and Prevention BV
Publication of JP2018529331A publication Critical patent/JP2018529331A/ja
Publication of JP2018529331A5 publication Critical patent/JP2018529331A5/ja
Application granted granted Critical
Publication of JP6975709B2 publication Critical patent/JP6975709B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018511416A 2015-09-02 2016-09-01 安定化したウイルスクラスｉ融合タンパク質 Active JP6975709B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562213466P 2015-09-02 2015-09-02
US62/213,466 2015-09-02
PCT/EP2016/070654 WO2017037196A1 (en) 2015-09-02 2016-09-01 Stabilized viral class i fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020188363A Division JP2021045138A (ja) 2015-09-02 2020-11-12 安定化したウイルスクラスｉ融合タンパク質

Publications (3)

Publication Number Publication Date
JP2018529331A JP2018529331A (ja) 2018-10-11
JP2018529331A5 JP2018529331A5 (cg-RX-API-DMAC7.html) 2019-08-08
JP6975709B2 true JP6975709B2 (ja) 2021-12-01

Family

ID=56855456

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018511416A Active JP6975709B2 (ja) 2015-09-02 2016-09-01 安定化したウイルスクラスｉ融合タンパク質
JP2020188363A Pending JP2021045138A (ja) 2015-09-02 2020-11-12 安定化したウイルスクラスｉ融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020188363A Pending JP2021045138A (ja) 2015-09-02 2020-11-12 安定化したウイルスクラスｉ融合タンパク質

Country Status (7)

Country Link
US (2) US10538557B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019044A3 (cg-RX-API-DMAC7.html)
JP (2) JP6975709B2 (cg-RX-API-DMAC7.html)
CN (1) CN108025057B (cg-RX-API-DMAC7.html)
AU (2) AU2016316723B2 (cg-RX-API-DMAC7.html)
CA (1) CA2997181A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017037196A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102758377B1 (ko) 2015-09-03 2025-01-23 노바백스, 인코포레이티드 개선된 안정성 및 면역원성을 갖는 백신 조성물
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
IL305911B2 (en) 2018-03-19 2025-01-01 Novavax Inc Multifunctional nanoparticle influenza vaccines
WO2020035497A1 (en) 2018-08-13 2020-02-20 Janssen Vaccines & Prevention B.V. Stabilized filovirus glycoprotein trimers
CN109142723B (zh) * 2018-08-21 2021-07-13 苏州华益美生物科技有限公司 人类免疫缺陷病毒快速检测测试卡及其应用
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021228842A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
CN116096409A (zh) 2020-05-11 2023-05-09 杨森制药公司 编码稳定化的冠状病毒刺突蛋白的rna复制子
MX2022014161A (es) 2020-05-11 2022-12-02 Janssen Pharmaceuticals Inc Vacunas contra sars-cov-2.
BR112022023591A2 (pt) * 2020-05-29 2022-12-27 Univ Texas Proteína spike (s) do coronavírus modificada e métodos de uso da mesma
CN111704657B (zh) * 2020-06-16 2021-11-09 四川安可瑞新材料技术有限公司 Hiv-2重组抗原及其制备方法、用途
WO2022008438A1 (en) 2020-07-06 2022-01-13 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2022032274A1 (en) * 2020-08-02 2022-02-10 Richard Ascione Vaccine compositions for influenza viruses and methods of use
JP2024512766A (ja) * 2021-03-30 2024-03-19 ベイラー カレッジ オブ メディスン 高力価ポリペプチドベースのタンパク質阻害のための方法および組成物
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用
WO2025051975A1 (en) * 2023-09-06 2025-03-13 Sanofi Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP2285408B1 (en) * 2008-06-05 2018-10-24 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
SG194755A1 (en) * 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
SG11201400999VA (en) * 2011-09-30 2014-07-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
JP6294828B2 (ja) * 2011-11-28 2018-03-14 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスワクチンおよびその使用
AU2014259474B2 (en) * 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) * 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Also Published As

Publication number Publication date
JP2018529331A (ja) 2018-10-11
AU2016316723A1 (en) 2018-02-22
EP3344288A1 (en) 2018-07-11
AU2021201330A1 (en) 2021-03-18
EP4019044A3 (en) 2022-08-24
US20180346521A1 (en) 2018-12-06
WO2017037196A1 (en) 2017-03-09
US10711042B2 (en) 2020-07-14
CN108025057B (zh) 2023-04-18
CA2997181A1 (en) 2017-03-09
AU2016316723B2 (en) 2021-03-25
US20200115421A1 (en) 2020-04-16
EP4019044A2 (en) 2022-06-29
CN108025057A (zh) 2018-05-11
JP2021045138A (ja) 2021-03-25
US10538557B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
JP6975709B2 (ja) 安定化したウイルスクラスｉ融合タンパク質
US12331077B2 (en) Stabilized pre-fusion RSV F proteins
AU2014259474B2 (en) Stabilized soluble prefusion RSV F polypeptides
AU2021232702B2 (en) Stabilized pre-fusion RSV F proteins
CN107847580A (zh) 针对rsv的疫苗
EA034653B1 (ru) Стабилизированные растворимые f-полипептиды rsv перед слиянием
EA035909B1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
WO2017207477A1 (en) Stabilized pre-fusion rsv f proteins
CN121013729A (zh) 不具有异源三聚化结构域的稳定化的三聚rsv融合蛋白
US20240228548A9 (en) Stabilized pre-fusion rsv fb antigens
CN117460527A (zh) 稳定化的融合前rsv fb抗原
OA19273A (en) Stabilized pre-fusion RSV F proteins.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211108

R150 Certificate of patent or registration of utility model

Ref document number: 6975709

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250